Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mycobacterium Abscessus Pulmonary Disease

Conditions

Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections, Non-Tuberculous Mycobacteria Pulmonary Disease

Trial Timeline

Apr 1, 2027 → Jul 1, 2031

NCT ID

NCT07485010

About Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin

Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin is a phase 2 stage product being developed by Innoviva for Mycobacterium Abscessus Pulmonary Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07485010. Target conditions include Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07485010	Phase 2	Recruiting	Apr 1, 2027	Jul 1, 2031	Mycobacterium Abscessus Pulmonary Disease

Competing Products

20 competing products in Mycobacterium Abscessus Pulmonary Disease

See all competitors

Product	Company	Stage	Hype Score
Trifluridine	Amgen	Pre-clinical	22
clarithromycin, rifabutin	Pfizer	Approved	84
Azithromycin	Pfizer	Pre-clinical	22
Ethambutol hydrochloride + Clarithromycin + Azithromycin	Pfizer	Phase 3	76
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Approved	84
Tigecycline	Pfizer	Phase 2	51
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	84
ALIS + Azithromycin + Ethambutol + ELC	Insmed	Phase 3	74
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)	Insmed	Phase 3	74
LAI plus multi-drug regimen	Insmed	Phase 2	49
Liposomal amikacin for inhalation (LAI) + placebo	Insmed	Phase 2	49
LAI (Liposomal Amikacin for Inhalation) 590 mg	Insmed	Phase 3	74
Molgramostim nebulizer solution	Savara	Phase 2	47
Inhaled molgramostim + Antimycobacterial regimen	Savara	Phase 2	47
Epetraborole + Epetraborole + Placebo + Placebo	AN2 Therapeutics	Phase 2	44
SPR720 + Placebo + Open-label Standard of Care	Spero Therapeutics	Phase 2	44
RHB-204 + Placebo	RedHill Biopharma	Phase 3	69

Other Products from Innoviva

Angiotensin-IIApproved

Eravacycline 2mg/kg + Eravacycline 1.5mg/kgPhase 2

Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) + Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) + Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)Phase 1